119 related articles for article (PubMed ID: 9089338)
1. Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.
Shiosaki K; Lin CW; Kopecka H; Bianchi B; Miller T; Stashko M; Witte D
J Med Chem; 1997 Mar; 40(7):1169-72. PubMed ID: 9089338
[TBL] [Abstract][Full Text] [Related]
2. Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.
Shiosaki K; Lin CW; Kopecka H; Tufano MD; Bianchi BR; Miller TR; Witte DG; Nadzan AM
J Med Chem; 1991 Sep; 34(9):2837-42. PubMed ID: 1716682
[TBL] [Abstract][Full Text] [Related]
3. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
4. Conformational analysis of CCK-B agonists using 1H-NMR and restrained molecular dynamics: comparison of biologically active Boc-Trp-(N-Me) Nle-Asp-Phe-NH2 and inactive Boc-Trp-(N-Me)Phe-Asp-Phe-NH2.
Goudreau N; Weng JH; Roques BP
Biopolymers; 1994 Feb; 34(2):155-69. PubMed ID: 8142585
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
6. Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.
Shiosaki K; Lin CW; Kopecka H; Craig RA; Bianchi BR; Miller TR; Witte DG; Stashko M; Nadzan AM
J Med Chem; 1992 May; 35(11):2007-14. PubMed ID: 1375964
[TBL] [Abstract][Full Text] [Related]
7. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
[TBL] [Abstract][Full Text] [Related]
9. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
Dezube M; Sugg EE; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; James MK; Johnson MF; Mosher JT
J Med Chem; 1995 Aug; 38(17):3384-90. PubMed ID: 7650691
[TBL] [Abstract][Full Text] [Related]
10. CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.
Bennett MJ; Nikkel AL; Bianchi BR; Miller TR; Bednarz L; Witte DG; Stashko M; Wang SS; Gore PA; Asin KE
J Med Chem; 1994 May; 37(11):1569-71. PubMed ID: 8201591
[TBL] [Abstract][Full Text] [Related]
11. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.
Horwell DC; Beeby A; Clark CR; Hughes J
J Med Chem; 1987 Apr; 30(4):729-32. PubMed ID: 3560164
[TBL] [Abstract][Full Text] [Related]
14. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
Sugg EE; Kimery MJ; Ding JM; Kenakin DC; Miller LJ; Queen KL; Rimele TJ
J Med Chem; 1995 Jan; 38(1):207-11. PubMed ID: 7837233
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
Bellier B; McCort-Tranchepain I; Ducos B; Danascimento S; Meudal H; Noble F; Garbay C; Roques BP
J Med Chem; 1997 Nov; 40(24):3947-56. PubMed ID: 9397175
[TBL] [Abstract][Full Text] [Related]
16. [Conformational-functional relationships of tetragastrin analogs].
Nikiforovich GV; Liepinia IT; Tseĭtin VM; Shenderovich MD; Galaktionov SG
Bioorg Khim; 1991 May; 17(5):626-36. PubMed ID: 1768290
[TBL] [Abstract][Full Text] [Related]
17. Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide.
Cannon JB; Adjei LA; Lu MY; Garren K
J Drug Target; 1996; 4(2):69-78. PubMed ID: 8894966
[TBL] [Abstract][Full Text] [Related]
18. Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors.
Haskell-Luevano C; Nikiforovich G; Sharma SD; Yang YK; Dickinson C; Hruby VJ; Gantz I
J Med Chem; 1997 May; 40(11):1738-48. PubMed ID: 9171884
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
[TBL] [Abstract][Full Text] [Related]
20. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
